Work

A phase 1 study of intermittently administered pazopanib in combination with continuous daily dosing of lapatinib in patients with solid tumors

Year: 2015

Type: article

Study design: Clinical Trial

Source: Cancer Chemotherapy and Pharmacology

DOI: 10.1007/s00280-015-2824-6

Authors: H. Henary, G. C. George, J. Wheler, A. Naing, S. Piha-Paul, S. Fu, R. Mistry, R. Zinner, R. Kurzrock, D. S. Hong

Institutions: The University of Texas MD Anderson Cancer Center, University of California San Diego, Moores Cancer Center

Language: English

Topic: HER2/EGFR in Cancer Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W978267315

FWCI:

Cites: 16

Cited by: 2

Related to: 10